Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This drug is a combination ophthalmic formulation containing polyethylene glycol 400, propylene glycol, dextran, and hypromellose. It is used as an artificial tear or eye lubricant to relieve symptoms of dry eyes such as burning, irritation, and discomfort. Each component acts as a demulcent or humectant to moisten the ocular surface and form a protective layer over the mucous membrane of the eye. Polyethylene glycol 400 and propylene glycol are polyol demulcents that help retain moisture on the ocular surface[5][7][8]. Dextran and hypromellose (also known as hydroxypropyl methylcellulose) are polysaccharide polymers that further enhance viscosity and prolong retention time on the cornea[2][5]. The combination works by supplementing natural tears, reducing evaporation from the eye surface, protecting against environmental irritants, and providing symptomatic relief for dry eye conditions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on polyethylene glycol 400 + propylene glycol + dextran + hypromellose.